The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure
- 1 September 2000
- journal article
- clinical trial
- Published by Elsevier in International Journal of Cardiology
- Vol. 75 (2-3) , 167-176
- https://doi.org/10.1016/s0167-5273(00)00319-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1999
- Prospective Study of Heart Rate Variability and Mortality in Chronic Heart FailureCirculation, 1998
- Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular DysfunctionCirculation, 1996
- Heart rate variability: Standards of measurement, physiological interpretation, and clinical useEuropean Heart Journal, 1996
- A Second Generation of Centrally Acting Antihypertensive Agents Act on Putative I1-Imidazoline ReceptorsJournal of Cardiovascular Pharmacology, 1992
- Moxonidine: A Second Generation of Centrally Acting DrugsJournal of Cardiovascular Pharmacology, 1992
- Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.Circulation, 1986
- Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity.Circulation, 1986
- Effects of catecholamines on lactic acid output during progressive working contractionsJournal of Applied Physiology, 1985
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984